105 related articles for article (PubMed ID: 1445752)
1. In vitro and in vivo antitumoral activity of alkylphosphonates.
Ries UJ; Fleer EA; Breiser A; Unger C; Stekar J; Fenneberg K; Eibl H
Eur J Cancer; 1992; 29A(1):96-101. PubMed ID: 1445752
[TBL] [Abstract][Full Text] [Related]
2. Is metabolism an important arbiter of anticancer activity of ether lipids? Metabolism of SRI 62-834 and hexadecylphosphocholine by [31P]-NMR spectroscopy and comparison of their cytotoxicities with those of their metabolites.
Bishop FE; Dive C; Freeman S; Gescher A
Cancer Chemother Pharmacol; 1992; 31(2):85-92. PubMed ID: 1451237
[TBL] [Abstract][Full Text] [Related]
3. Hexadecylphosphocholine, a new ether lipid analogue. Studies on the antineoplastic activity in vitro and in vivo.
Unger C; Damenz W; Fleer EA; Kim DJ; Breiser A; Hilgard P; Engel J; Nagel G; Eibl H
Acta Oncol; 1989; 28(2):213-7. PubMed ID: 2736110
[TBL] [Abstract][Full Text] [Related]
4. Tumor heterogeneity and chemosensitivity to cyclophosphamide, vinblastine and hexadecylphosphocholine.
Angres G; Scherf HR; Schmähl D
Cancer Treat Rev; 1990 Sep; 17(2-3):339-45. PubMed ID: 2272049
[No Abstract] [Full Text] [Related]
5. Hexadecylphosphocholine: a new and selective antitumor drug.
Eibl H; Unger C
Cancer Treat Rev; 1990 Sep; 17(2-3):233-42. PubMed ID: 2272038
[TBL] [Abstract][Full Text] [Related]
6. D-21266, a new heterocyclic alkylphospholipid with antitumour activity.
Hilgard P; Klenner T; Stekar J; Nössner G; Kutscher B; Engel J
Eur J Cancer; 1997 Mar; 33(3):442-6. PubMed ID: 9155530
[TBL] [Abstract][Full Text] [Related]
7. Hexadecylphosphocholine: preclinical and the first clinical results of a new antitumor drug.
Unger C; Eibl H
Lipids; 1991 Dec; 26(12):1412-7. PubMed ID: 1819743
[TBL] [Abstract][Full Text] [Related]
8. Structure-activity relationships of four anti-cancer alkylphosphocholine derivatives in vitro and in vivo.
Sobottka SB; Berger MR; Eibl H
Int J Cancer; 1993 Feb; 53(3):418-25. PubMed ID: 8428795
[TBL] [Abstract][Full Text] [Related]
9. Systemic administration of alkylphosphocholines. Erucylphosphocholine and liposomal hexadecylphosphocholine.
Kaufmann-Kolle P; Berger MR; Unger C; Eibl H
Adv Exp Med Biol; 1996; 416():165-8. PubMed ID: 9131143
[No Abstract] [Full Text] [Related]
10. Alkylphosphocholines: a new class of membrane-active anticancer agents.
Hilgard P; Klenner T; Stekar J; Unger C
Cancer Chemother Pharmacol; 1993; 32(2):90-5. PubMed ID: 8485813
[No Abstract] [Full Text] [Related]
11. Alkyl phosphocholines: toxicity and anticancer properties.
Muschiol C; Berger MR; Schuler B; Scherf HR; Garzon FT; Zeller WJ; Unger C; Eibl HJ; Schmähl D
Lipids; 1987 Nov; 22(11):930-4. PubMed ID: 3444388
[TBL] [Abstract][Full Text] [Related]
12. Hexadecylphosphocholine does not influence phospholipase D and sphingomyelinase activity in human leukemia cells.
Berkovic D; Berkovic K; Binder C; Haase D; Fleer EA
J Exp Ther Oncol; 2002; 2(4):213-8. PubMed ID: 12416025
[TBL] [Abstract][Full Text] [Related]
13. Synthesis of alkylphosphonates, a new class of antineoplastic agents.
Ries UJ; Fleer EA; Eibl H
Chem Phys Lipids; 1992 May; 61(3):225-34. PubMed ID: 1525962
[TBL] [Abstract][Full Text] [Related]
14. Characterization of the antitumor activity of hexadecylphosphocholine (D 18506).
Hilgard P; Stekar J; Voegeli R; Engel J; Schumacher W; Eibl H; Unger C; Berger MR
Eur J Cancer Clin Oncol; 1988 Sep; 24(9):1457-61. PubMed ID: 3141197
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic activity of ET-18-OCH3 and hexadecylphosphocholine against mammary tumors in BD-VI rats.
Scherf HR; Schuler B; Berger MR; Schmähl D
Lipids; 1987 Nov; 22(11):927-9. PubMed ID: 3444387
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic behavior and antineoplastic activity of liposomal hexadecylphosphocholine.
Kaufmann-Kolle P; Drevs J; Berger MR; Kötting J; Marschner N; Unger C; Eibl H
Cancer Chemother Pharmacol; 1994; 34(5):393-8. PubMed ID: 8070005
[TBL] [Abstract][Full Text] [Related]
17. Hexadecylphosphocholine differs from conventional cytostatic agents.
Berger MR; Betsch B; Gebelein M; Amtmann E; Heyl P; Scherf HR
J Cancer Res Clin Oncol; 1993; 119(9):541-8. PubMed ID: 8392075
[TBL] [Abstract][Full Text] [Related]
18. Antineoplastic activity in vitro of free and liposomal alkylphosphocholines.
Zeisig R; Jungmann S; Arndt D; Schütt A; Nissen E
Anticancer Drugs; 1993 Feb; 4(1):57-64. PubMed ID: 8457716
[TBL] [Abstract][Full Text] [Related]
19. Evidence for abrogation of oncogene-induced radioresistance of mammary cancer cells by hexadecylphosphocholine in vitro.
Bruyneel EA; Storme GA; Schallier DC; Van den Berge DL; Hilgard P; Mareel MM
Eur J Cancer; 1993; 29A(14):1958-63. PubMed ID: 8280489
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of alkylphosphocholines and analogues in methylnitrosourea-induced rat mammary carcinomas.
Berger MR; Yanapirut P; Reinhardt M; Klenner T; Scherf HR; Schmeiser HH; Eibl H
Prog Exp Tumor Res; 1992; 34():98-115. PubMed ID: 1438807
[No Abstract] [Full Text] [Related]
[Next] [New Search]
